ReviewMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2018
Novel triazoles of 3-acetylbetulin and betulone as anticancer agents.
Review in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 42 citations in OpenAlex.
- Novel C3/C28-bis-1,2,4-Triazolyl-sulfanylacetate-betulin Derivatives: Synthesis and Evaluation of Anticancer Potential.International journal of molecular sciences · 2026Article
- Triazole-based hybrid molecules in anticancer drug discovery: structural classes and mechanistic insights, 2014-2025.Beilstein journal of organic chemistry · 2026Review
- Click Chemistry: an overview and recent updates in the medicinal attributes of click-derived heterocycles.Molecular diversity · 2025Review
- Synthesis and Anticancer Activity of Indole-Functionalized Derivatives of Betulin.Pharmaceutics · 2022Article
- Semisynthetic Derivatives of Pentacyclic Triterpenes Bearing Heterocyclic Moieties with Therapeutic Potential.Molecules (Basel, Switzerland) · 2022Review
- Review
- Bile-Acid-Appended Triazolyl Aryl Ketones: Design, Synthesis, In Vitro Anticancer Activity and Pharmacokinetics in Rats.Molecules (Basel, Switzerland) · 2021Article
- Supported Silver Nanoparticles as Catalysts for Liquid-Phase Betulin Oxidation.Nanomaterials (Basel, Switzerland) · 2021Article
- Dataset onData in brief · 2021Article
- In Vitro Calli Production Resulted in Different Profiles of Plant-Derived Medicinal Compounds inMolecules (Basel, Switzerland) · 2020Article
- 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.Bioorganic & medicinal chemistry · 2019Review
- Biological Activity and In Silico Study of 3-Modified Derivatives of Betulin and Betulinic Aldehyde.International journal of molecular sciences · 2019Article
- Recent Developments in the Functionalization of Betulinic Acid and Its Natural Analogues: A Route to New Bioactive Compounds.Molecules (Basel, Switzerland) · 2019Review
- Application of TLC for Evaluation of the Lipophilicity of Newly Synthetized Esters: Betulin Derivatives.Journal of analytical methods in chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CuAAC reaction of azides and acetylenic triterpenes was used for synthesis of new triazoles of 3-acetylbetulin and betulone. The triazole derivatives were evaluated for their anticancer activity in vitro against amelanotic melanoma C-32, ductal carcinoma T47D and glioblastoma SNB-19 cell lines. 28-[1-(3'-Deoxythymidine-5'-yl)-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.